Myelodysplastic syndromes (MDS) represent a group of malignant hematologic diseases characterized by ineffective hematopoiesis, meaning the bone marrow fails to produce healthy, fully functioning blood cells [1]. Because this condition primarily affects the elderly, many cases are initially discovered incidentally through routine blood counts [6]. However, the disease frequently presents with prominent clinical features tied to deficiencies in various blood cell lines [6].
Core Signs and Symptoms of MDS
The primary clinical manifestations of myelodysplastic syndromes stem from low blood cell counts, specifically involving red blood cells, white blood cells, and platelets [6]. Because the hematopoietic tissue is dysfunctional, the pathological effect can sometimes be greater than the numerical counts might suggest, occasionally leading to bleeding or infection even when neutrophil or platelet counts appear normal [6]. Common signs include:
- Chronic anemia, leading to persistent fatigue and weakness
- Neutropenia, which can increase vulnerability to infections and occult abscesses
- Thrombocytopenia, raising the risk of bruising and bleeding complications
Additionally, up to 30% of patients with myelodysplastic syndromes may eventually progress to acute myeloid leukemia (AML) [1].
The Role of Red Blood Cell Transfusions
Due to ineffective red blood cell production, many individuals with MDS develop chronic anemia and subsequent transfusion dependency [1]. Systematic literature reviews and meta-analyses indicate a consistent link between transfusion dependency and overall survival outcomes [1]. Specifically, studies show a decrease in overall survival in transfusion-dependent patients compared to those who are transfusion-independent, while patients who achieve transfusion independence through treatment tend to experience better prognoses [1].
Broader Clinical Impact
Beyond the direct physical toll of anemia and fatigue, the necessity for regular blood support shapes the overall course of the disease. Research highlights that transfusion dependency carries a broader humanistic, clinical, and economic burden for patients [1]. Managing these needs requires ongoing monitoring by healthcare professionals to evaluate changes in transfusion status and overall health stability.
Sources
- 1. Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis
- 2. Plasma cell leukemia and hyperviscosity syndrome
- 3. Hematological support in patients undergoing allogenetic bone marrow transplantation
- 6. Clinical features of MDS